Literature DB >> 1525248

Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis.

N Kapel1, D Meillet, L Favennec, D Magne, D Raichvarg, J G Gobert.   

Abstract

The intestinal clearance of alpha 1-antiproteinase, monomeric IgA and IgG, and the daily fecal output of polymeric IgA and IgM were investigated in patients with inflammatory bowel diseases (inactive and active Crohn's disease, ulcerative colitis) and in a control group. The intestinal clearance of alpha 1-antiproteinase was significantly increased in all patients with inflammatory bowel diseases (p less than 0.01), irrespective of the grade of the disease. In contrast, increases in intestinal clearances of monomeric IgA and IgG were more closely related to the severity of the intestinal lesions. The associate determination of these three quantities should therefore be of interest for monitoring the degree of intestinal bowel inflammation. Faecal output of polymeric IgA was significantly increased in active intestinal disease (p less than 0.01), whereas faecal IgM levels were not. The determination of the faecal output of polymeric IgA should contribute to the assessment of the activity of inflammatory bowel diseases, and may provide insight into the activation of the mucosal immune system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525248     DOI: 10.1515/cclm.1992.30.4.197

Source DB:  PubMed          Journal:  Eur J Clin Chem Clin Biochem        ISSN: 0939-4974


  13 in total

1.  Clinical significance of inflammatory markers.

Authors:  Bincy P Abraham; Selvi Thirumurthi
Journal:  Curr Gastroenterol Rep       Date:  2009-10

Review 2.  Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming.

Authors:  Diane R Mould; Richard N Upton; Jessica Wojciechowski; Becky L Phan; Stacy Tse; Marla C Dubinsky
Journal:  AAPS J       Date:  2018-06-14       Impact factor: 4.009

Review 3.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

4.  Technical report: results of immunological tests on faecal extracts are likely to be extremely misleading.

Authors:  A Ferguson; K A Humphreys; N M Croft
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

5.  Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.

Authors:  Soon Man Yoon; Talin Haritunians; Sultan Chhina; Zhenqiu Liu; Shaohong Yang; Carol Landers; Dalin Li; Byong Duk Ye; David Shih; Eric A Vasiliauskas; Andrew Ippoliti; Shervin Rabizadeh; Stephan R Targan; Gil Y Melmed; Dermot P B McGovern
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

6.  Fecal lysozyme in assessment of disease activity in inflammatory bowel disease.

Authors:  A van der Sluys Veer; J Brouwer; I Biemond; G E Bohbouth; H W Verspaget; C B Lamers
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

7.  A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.

Authors:  Fei Hua; Jakob Ribbing; Walter Reinisch; Fabio Cataldi; Steven Martin
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

8.  Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.

Authors:  Cheryl Li; Satoshi Shoji; Jean Beebe
Journal:  Br J Clin Pharmacol       Date:  2018-06-25       Impact factor: 4.335

9.  Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in Mice.

Authors:  Yujie Yang; Tommy R Li; Joseph P Balthasar
Journal:  AAPS J       Date:  2017-08-28       Impact factor: 4.009

Review 10.  Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.

Authors:  Helena Edlund; Johanna Melin; Zinnia P Parra-Guillen; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.